ENDRA Life Sciences (NDRA)
Developing radio-frequency thermoacoustic ultrasound for point-of-care liver-fat measurement.
Something off on this page? Send us feedback.
Develops the TAEUS Liver system, which pairs radio-frequency thermoacoustics with conventional ultrasound to estimate liver fat for metabolic-disease assessment and clinical-trial screening. Its current business remains pre-revenue and dependent on regulatory authorization, resources, external partners, and a pending merger.
Develops the TAEUS platform, which combines pulsed radio-frequency energy, ultrasound sensors, and proprietary algorithms to assess tissue composition. Its lead TAEUS Liver/FLIP device is designed to work beside conventional ultrasound to estimate liver fat for metabolic-disease assessment, therapy-response monitoring, and clinical-trial screening. Other uses, including temperature monitoring, vascular imaging, and perfusion analysis, remain in development.
Plans subscription arrangements, capital-equipment sales with service and upgrades, and potential licensing to ultrasound or thermoablation equipment makers, subject to regulatory approval and resources. U.S. FDA marketing authorization and EU MDR recertification remain requirements; a pending merger could change the business focus.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.7M · Total debt $429.3K · Total assets $7.9M · Shareholders' equity $6.3M
- Revenue
- $0
- Operating income
- −$1.5M
- Net income
- $159.9K
No dividends on record.
| Insiders | 31.76% | 403.4K shares | |
|---|---|---|---|
| 5 holders · as of Mar 4, 2026 | |||
| Strategic holders | 0.00% | 6 shares | |
| 1 holder · as of Feb 14, 2019 | |||
| Other | 68.24% | 866.7K shares | |
| remainder | |||
1.27M company shares as of Sep 12, 2026 · holders as of their latest filing
Two share counts disagree (1.50M in the company's Sep 22, 2026 report, 1.27M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Anthony DigiandomenicoInsiderdirector | 10.75% | 136,589 | filed Jan 23, 2026 |
ATW Master Fund V LPInstitution | 9.14% | 116,024 | filed Oct 28, 2025 |
Alexander Y. TokmanInsiderdirector, officer: Chief Executive Officer | 8.03% | 101,926 | filed Mar 4, 2026 |
Michael HarshInsiderdirector | 5.17% | 65,710 | filed Jan 23, 2026 |
Lou BaseneseInsiderdirector | 5.17% | 65,709 | filed Jan 23, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- GE HealthCare
Broad imaging alternatives for liver-fat assessment.
- Philips (ADR)
Established imaging alternatives for non-invasive liver assessment.
- Medtronic
Thermal-ablation monitoring alternative in a developmental use case.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ENDRA Life Sciences | $5.97 | −5.39% | $8.0M | — | — | — | — |
| GE HealthCare | $66.52 | +2.64% | $29.27B | 18.8 | 12.8 | 1.4 | +5.8% |
| Philips (ADR) | $24.90 | −0.02% | $24.34B | 18.7 | 12.9 | 1.2 | −2.8% |
| Medtronic | $91.62 | −0.14% | $117.44B | 22.6 | 15.3 | 3.1 | +13.7% |
| Median | 18.8 | 12.9 | 1.4 | +5.8% |